Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

17 March 2021

More deals, higher prices lead to greater antitrust scrutiny for pharma M&A

Kristen Hallam and Kris Elaine Figuracion for S&P Global Market Intelligence cover the U.S. Federal Trade Commission's efforts to revise the way they, along with Canada, the U.K. and Europe, study the impact of pharmaceutical mergers and acquisitions (M&A).

The article reports on new efforts from the U.S. Federal Trade Commission (FTC) to add to the standard criteria of product and pipeline that is normally assessed when reviewing pharma's M&A. The FTC hopes to implement the inclusion of pharma companies' transaction's effects on prices and access to medicines for consumers.

Damiano de Felice, Director of Strategy at the Access to Medicine Foundation, comments on the effects that access barriers can have on the pharmaceutical industry:

"When governments see that access barriers are not addressed for important products controlled by certain companies, it is natural to expect that they will consider more aggressive approaches to ensure that the industry continues to earn its social license to operate."

Click to read the full article. 

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved